Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2011

01-12-2011 | Review

Cardiovascular toxicity of anti-angiogenic drugs

Authors: Gaetan des Guetz, Bernard Uzzan, Kader Chouahnia, Jean-François Morère

Published in: Targeted Oncology | Issue 4/2011

Login to get access

Abstract

Anti-angiogenic targeted therapies are now major tools in the management of solid tumors. Briefly, one can distinguish between monoclonal antibodies such as bevacizumab directed against vascular endothelial growth factor (VEGF) and small molecules such as those targeted against receptors with tyrosine-kinase activity. Soon after they were marketed, these drugs showed cardiovascular toxicities, such as hypertension, left ventricular systolic dysfunction, heart failure and conduction abnormalities. The most frequent cardiovascular side effect of targeted therapies is hypertension, but the most life-threatening is QT prolongation with its risk of torsade de pointe and sudden cardiac death. Since the incidence of different types of cardiovascular side effects following targeted therapies varies across studies—and despite the fact that several meta-analyses attempted to summarize available information—those side effects are still not well identified. In addition, their reversibility is not precisely known. This review aims to present and discuss the various cardiovascular toxicities of anti-angiogenic targeted therapies for cancer.
Literature
1.
2.
des Guetz G, Uzzan B, Nicolas P et al (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94:1823–1832PubMedCrossRef
3.
Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434PubMedCrossRef
4.
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
5.
Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW et al (2004) Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis, and management. Circulation 109:3122–3131PubMedCrossRef
6.
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65PubMedCrossRef
7.
An MM, Zou Z, Shen H, Ping L et al (2010) Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated analysis. Eur J Clin Pharmacol 66:813–821PubMedCrossRef
8.
Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019PubMedCrossRef
9.
Veronese ML, Mosenkis A, Flaherty KT et al (2006) Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol 24:1363–1369PubMedCrossRef
10.
Wu S, Chen JJ, Kudelka A, Lu J et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117–123PubMedCrossRef
11.
Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17PubMedCrossRef
12.
Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system. Focus on hypertension. Circulation 124:1687–1691PubMedCrossRef
13.
Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19:927–934PubMedCrossRef
14.
Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186–193PubMedCrossRef
15.
Eremina V, Quaggin SE (2010) Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol 30:582–590PubMedCrossRef
16.
Eremina V, Jefferson JA, Kowalewska J, Hochster H et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136PubMedCrossRef
17.
Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–1239PubMedCrossRef
18.
Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 49:287–297PubMedCrossRef
19.
Hurwitz HI, Saltz LB, van Cutsem E et al (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29:1757–1754PubMedCrossRef
20.
Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285PubMedCrossRef
21.
Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27–38PubMedCrossRef
22.
Hang XF, Xu WS, Wang JX, Xin H et al (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 67:613–623PubMedCrossRef
23.
Franco TH, Khan A, Joshi V, Thomas B (2008) Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 4:1367–1370PubMed
24.
Choueiri TK, Mayer EL, Je Y, Rosenberg JE et al (2011) Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632–638PubMedCrossRef
25.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
26.
Motzer RJ, Rini BI, Bukowski RM, Curti BD et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524PubMedCrossRef
27.
Escudier B, Eisen T, Stadler WM, Szczylik C et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef
28.
Schmidinger M, Zielinski CC, Vogl UM, Bojic A et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212PubMedCrossRef
29.
Popat S, Smith IE (2008) Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nature Clin Pract 5:324–335
30.
Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. The Breast 13:173–183PubMedCrossRef
31.
Kiura K, Nakagawa K, Shinkai T et al (2008) A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3:386–393PubMedCrossRef
32.
Maitland ML, Bakris GL, Black HR et al (2010) Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. JNCI 102:596–604PubMed
33.
Galfrascoli E, Piva S, Cinquini M et al (2011) Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 43:286–294PubMedCrossRef
34.
Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 305:487–494PubMedCrossRef
35.
Boehm S, Rothermundt C, Hess D, Joerger M (2010) Antiangiogenic drugs in oncology: A focus on drug safety and the elderly-A mini-review. Gerontology 56:303–309PubMedCrossRef
36.
Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, et al (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol 2011 Feb 15 [Epub ahead of print]
Metadata
Title
Cardiovascular toxicity of anti-angiogenic drugs
Authors
Gaetan des Guetz
Bernard Uzzan
Kader Chouahnia
Jean-François Morère
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Targeted Oncology / Issue 4/2011
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-011-0204-7

Other articles of this Issue 4/2011

Targeted Oncology 4/2011 Go to the issue

Day-to-Day Practice

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

Review

Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents

Review

Pulmonary toxicities from targeted therapies: a review

Editorial

The carriages to the good drivers

Review

Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients

Review

Heart to heart with trastuzumab: a review on cardiac toxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits